genedrive plc

("genedrive" or the "Company")

Application for Listing

Total Voting Rights

genedrive plc (AIM:GDR), the point of care molecular diagnostics company, confirms that in order to support the further drawdown and delivery of its £5M Equity Prepayment facility that was announced on 31 March 2023, application has been made for the Admission to trading on AIM of 3,050,000 new Ordinary Shares of 1.5p each ("New Ordinary Shares").  Admission of the New Ordinary Shares ("Admission") is expected to occur on 10 August 2023.  Following Admission, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.  

Following Admission the Company's issued share capital will consist of 102,099,946 Ordinary Shares of 1.5p each and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further details please contact:

About genedrive plc (http://www.genedriveplc.com)  genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company are currently developing a genetic test for CYP2C19 metaboliser status.